(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Background: Although recent studies provide insight into the molecular mechanisms of the effects of ketamine, the antidepressant mechanism of ketamine enantiomers and their metabolites is not fully understood. In view of the involvement of mechanisms other than the N-methyl-D-aspartate receptor in ketamine’s action, we investigated the effects of (R)-ketamine, (S)-ketamine, (R)-norketamine [(R)-NK], (S)-NK, (2R,6R)-hydroxynorketamine [(2R,6R)-HNK], and (2S,6S)-HNK on monoaminergic neurotransmission in the prefrontal cortex of mice. Methods: The extracellular monoamine levels in the prefrontal cortex were measured by in vivo microdialysis. Results: (R)-Ketamine and (S)-ketamine acutely increased serotonin release in a dose-dependent manner, and the effect of (R)-ketamine was greater than that of (S)-ketamine. In contrast, (S)-ketamine caused a robust increase in dopamine release compared with (R)-ketamine. Both ketamine enantiomers increased noradrenaline release, but these effects did not differ. (2R,6R)-HNK caused a slight but significant increase in serotonin and noradrenaline but not dopamine release. (S)-NK increased dopamine and noradrenaline but not serotonin release. Differential effects between (R)-ketamine and (S)-ketamine were also observed in a lipopolysaccharide-induced model of depression. An α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antagonist, 2,3-dioxo-6-nitro-1,2,3,4- tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX), attenuated (S)-ketamine-induced, but not (R)-ketamine-induced serotonin release, whereas NBQX blocked dopamine release induced by both enantiomers. Local application of (R)-ketamine into the prefrontal cortex caused a greater increase in prefrontal serotonin release than that of (S)-ketamine. Conclusions: (R)-Ketamine strongly activates the prefrontal serotonergic system through an AMPA receptor-independent mechanism. (S)-Ketamine-induced serotonin and dopamine release was AMPA receptor-dependent. These findings provide a neurochemical basis for the underlying pharmacological differences between ketamine enantiomers and their metabolites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. The effects of (R)-ketamine, (S)-ketamine, and their metabolites on extracellular serotonin (5-HT) (A), dopamine (DA) (B), and noradrenaline (NA) (C) levels in the prefrontal cortex (PFC) of mice. (R)-ketamine (10, 20 mg/kg), (S)-ketamine (10, 20 mg/kg), (R)-norketamine [(R)-NK] (20 mg/kg), (S)-NK (20 mg/kg), (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] (20 mg/kg), (2S,6S)-HNK (20 mg/kg), or saline was i.p. injected at 0 minutes (arrow). Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with the saline-treated mice at each time point.](https://figures.cochat.ai/paper-figures/621c9bec90704718a8ce98eb7722bd3b/r-ketamine-induces-a-greater-increase-in-prefrontal-5-ht-release-than-s-ketamine-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For dopamine, (R)-ketamine (20 mg/kg) resulted in only modest changes, with a modest increase 40 minutes post-injection.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For serotonin, (R)-ketamine (10 and 20 mg/kg i.p.) produced an increase at 20-, 40-, and 60-minutes post-treatment with a peak effect size at ~275% of baseline following a 20 mg/kg dose at 20 minutes.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“(2R,6R)-HNK (20 mg/kg) increased serotonin at 40- and 60-minutes post-treatment with a peak effect at ~140% of baseline whereas (2S,6S)-HNK and (R) and (S)-norketamine (20 mg/kg) were ineffective.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The peak increases in dopamine by (R)-ketamine and peak increases in serotonin and dopamine by (S)-ketamine are prevented by the AMPAR antagonist NBQX pretreatment 20 minutes prior.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“norepinephrine levels were significantly impacted by (R)-ketamine (20 mg/kg) with a peak effect size of ~160% of baseline 40 minutes post-treatment and remained heightened following 120 minutes”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Ago et al., 2019
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,416
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
Guide for the care and use of laboratory animals
(1997) · Choice Reviews Online · doi:10.5860/choice.34-3310 · Cited by 2,922
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 2×
“Several molecular mechanisms underlying the antidepressant-like effects of ketamine have been proposed, especially focusing on the glutamatergic system such as synaptic or GluN2B-selective extra-synaptic NMDA receptor inhibition, inhibition of NMDA receptors localized on GABAergic interneurons, and the role of α-amino…”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 3×
“Since the AMPA receptor is suggested to be involved in the antidepressant-like effects of ketamine (Maeng et al., 2008; Chaki, 2017; Pałucha-Poniewiera, 2018; Zanos and Gould, 2018; Duman et al., 2019), we subsequently examined the effects of 2,3-dioxo-6-nitro-1,2,3,4- tetrahydrobenzo[f] quinoxaline-7-sulfonamide (NBQ…”
BackgroundMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“Accumulating evidence has indicated that the N-methyl-Daspartate (NMDA) receptor antagonist ketamine (racemic ketamine; (R,S)-ketamine) has rapid and potent antidepressant effects in major depressive disorder including treatment-resistant depression (Berman et al., 2000; Zarate et al., 2006a; Murrough et al., 2013; Ne…”
BackgroundDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationPrice, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Walker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432
Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431 · cited 1×
“(R,S)-Ketamine also produces antisuicidal effects in treatment-resistant depression (Price et al., 2009; Murrough et al., 2015; Grunebaum et al., 2018; Wilkinson et al., 2018).”
Zhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390 · cited 1×
“Previous studies have suggested the involvement of AMPA receptor activation in the antidepressant-like action of (R)ketamine, (S)-ketamine, and (R,S)-ketamine (Maeng et al., 2008; Koike et al., 2011; Walker et al., 2013; Koike and Chaki, 2014; Zhou et al., 2014; Yang et al., 2015; Zhang et al., 2016; Fukumoto et al.,…”
BackgroundA Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Self-citationKoike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.035 · Cited by 346
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297
Zhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu077 · Cited by 289
Self-citationEbert, B., Mikkelsen, S., Thorkildsen, C., & Borgbjerg, F. M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01116-3 · Cited by 270
Zarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Self-citationYang, C., Ren, Q., Qu, Y., Zhang, J.-C., Ma, M., Dong, C., & Hashimoto, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 250
Self-citationYang, C., Qu, Y., Fujita, Y., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0031-4 · Cited by 223
Self-citationHare, B. D., Shinohara, R., Liu, R. J., Pothula, S., DiLeone, R. J., & Duman, R. S. (2019) · Nature Communications · doi:10.1038/s41467-018-08168-9 · Cited by 217
Su, T.-P., Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Gueorguieva, R., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Krystal, J. H. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.94 · Cited by 209
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814709116 · Cited by 188 · cited 1×
“Some metabolites of ketamine, such as (S)-norketamine [(S)-NK] and (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] have been shown to exert antidepressant-like effects (Zanos et al., 2016; Chou et al., 2018; Pham et al., 2018; Yang et al., 2018a; Fukumoto et al., 2019).”
BackgroundKetamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
Gigliucci, V., O’Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3024-x · Cited by 177
Fukumoto, K., Iijima, M., & Chaki, S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.233 · Cited by 174
Koike, H., & Chaki, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.065 · Cited by 174
Yang, C., Qu, Y., Abe, M., Nozawa, D., Chaki, S., & Hashimoto, K. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.12.020 · Cited by 162
Self-citationNeurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0400-x · Cited by 154
Pham, T. H., Mendez-David, I., Defaix, C., Guiard, B. P., Tritschler, L., David, D. J., & Gardier, A. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.010 · Cited by 136
Pham, T. H., Defaix, C., Xu, X., Deng, S.-X., Fabresse, N., Alvarez, J.-C., Landry, D. W., Brachman, R. A., Denny, C. A., & Gardier, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.020 · Cited by 131
Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells
Nishimura, M., Sato, K., Okada, T., Yoshiya, I., Schloss, P., Shimada, S., & Tohyama, M. (1998) · Anesthesiology · doi:10.1097/00000542-199803000-00029 · Cited by 128
Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0692-7 · Cited by 127
Self-citationAMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 125
Self-citationSanacora, G., Johnson, M. R., Khan, A., Atkinson, S. D., Riesenberg, R. R., Schronen, J. P., Burke, M. A., Zajecka, J. M., Barra, L., Su, H.-L., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.224 · Cited by 120 · cited 1×
“However, other NMDA antagonists, including memantine and lanicemine, which bind to the receptor at the same site as ketamine, do not exhibit consistent evidence for clinical antidepressant efficacy (Zarate et al., 2006b, 2013; Smith et al., 2013; Newport et al., 2015; Sanacora et al., 2017).”
BackgroundWitkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233627 · Cited by 105
(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice
Yamaguchi, J.-I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., Mizuno-Yasuhira, A., & Chaki, S. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0084-y · Cited by 105
Self-citationChou, D., Peng, H.-Y., Lin, T.-B., Lai, C.-Y., Hsieh, M.-C., Wen, Y.-C., Lee, A.-S., Wang, H.-H., Yang, P.-S., Chen, G.-D., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.033 · Cited by 104
Zhang, K., Xu, T., Yuan, Z., Wei, Z., Yamaki, V. N., Huang, M., Huganir, R. L., & Cai, X. (2016) · Science Signaling · doi:10.1126/scisignal.aai7884 · Cited by 98 · cited 1×
“Previous studies have suggested the involvement of AMPA receptor activation in the antidepressant-like action of (R)ketamine, (S)-ketamine, and (R,S)-ketamine (Maeng et al., 2008; Koike et al., 2011; Walker et al., 2013; Koike and Chaki, 2014; Zhou et al., 2014; Yang et al., 2015; Zhang et al., 2016; Fukumoto et al.,…”
Backgrounddu Jardin, K. G., Liebenberg, N., Müller, H. K., Elfving, B., Sánchez, C., & Wegener, G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4327-5 · Cited by 93
Fukumoto, K., Iijima, M., Funakoshi, T., & Chaki, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx116 · Cited by 90
Nishitani, N., Nagayasu, K., Asaoka, N., Yamashiro, M., Shirakawa, H., Nakagawa, T., & Kaneko, S. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000649 · Cited by 87
Smith, E. G., Deligiannidis, K. M., Ulbricht, C. M., Landolin, C. S., Patel, J. K., & Rothschild, A. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08252 · Cited by 82
Ketamine stereoselectively inhibits rat dopamine transporter
Nishimura, M., & Sato, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00688-6 · Cited by 79
Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., & Domino, E. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.176 · Cited by 76
Ago, Y., Araki, R., Tanaka, T., Sasaga, A., Nishiyama, S., Takuma, K., & Matsuda, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.52 · Cited by 69
Self-citationHara, Y., Ago, Y., Taruta, A., Katashiba, K., Hasebe, S., Takano, E., Onaka, Y., Hashimoto, H., Matsuda, T., & Takuma, K. (2016) · Autism Research · doi:10.1002/aur.1596 · Cited by 59
Self-citationWatt, M. J., Roberts, C. L., Scholl, J. L., Meyer, D. L., Miiller, L. C., Barr, J. L., Novick, A. M., Renner, K. J., & Forster, G. L. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3353-9 · Cited by 57
Zhao, Y., & Sun, L. (2008) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2007.11.007 · Cited by 56
du Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.05.007 · Cited by 53
Ago, Y., Nakamura, S., Baba, A., & Matsuda, T. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300567 · Cited by 52
Self-citationAraki, R., Ago, Y., Hasebe, S., Nishiyama, S., Tanaka, T., Oka, S., Takuma, K., & Matsuda, T. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001582 · Cited by 52
Self-citationZhang, K., Dong, C., Fujita, Y., Fujita, A., & Hashimoto, K. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx100 · Cited by 48
Self-citationRogóż, Z. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71515-9 · Cited by 40
Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
Chaki, S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170221101054 · Cited by 40
Kinoshita, H., Nishitani, N., Nagai, Y., Andoh, C., Asaoka, N., Kawai, H., Shibui, N., Nagayasu, K., Shirakawa, H., Nakagawa, T., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy007 · Cited by 38
Pałucha-Poniewiera, A. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.02.011 · Cited by 36
Furuyashiki, T. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.12r09cp · Cited by 30
Ketamine Mechanism of Action: Separating the Wheat from the Chaff
Gould, T. D., Zanos, P., & Zarate, C. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.210 · Cited by 24 · cited 1×
“, 2018), although (2R,6R)-HNK does not bind to NMDA receptors at antidepressant-relevant concentrations (Gould et al., 2017).”
BackgroundChang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S., Xiong, Z., Shirayama, Y., & Hashimoto, K. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01012-1 · Cited by 20
Self-citationPsychopharmacology of combined activation of the serotonin 1A and σ 1 receptors
Ago, Y., Hasebe, S., Hiramatsu, N., Hashimoto, H., Takuma, K., & Matsuda, T. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.035 · Cited by 20
Self-citationTanaka, T., Ago, Y., Umehara, C., Imoto, E., Hasebe, S., Hashimoto, H., Takuma, K., & Matsuda, T. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw115 · Cited by 15
Self-citation
Cited by
Ketamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 246
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Self-citationMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
A historical review of antidepressant effects of ketamine and its enantiomers
Wei, Y., Chang, L., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172870 · Cited by 157
Self-citation
Metadata
- Authors
- Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., Nakazawa, T., Nakagawa, S., Hashimoto, K., & Hashimoto, H.
- Affiliations
- The University of Osaka (JP)
- Kanazawa University (JP)
- Corresponding author
- Ago, Yukio
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-21
- Volume
- 22
- Issue
- 10
- Pages
- 665-674
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6822138
- OpenAlex
- W2966617845
- Cited by
- 92
- References
- 71
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 11 · 2023: 16 · 2022: 15 · 2021: 15 · 2020: 13 · 2019: 1
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (JP16K08268, JP17K19488, JP17H03989)
- Ministry of Education, Culture, Sports, Science and Technology (JP18H05416, JP19dm0107122, JP19dm0207061, JP19dm0107119)
- Takeda Science Foundation
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine enantiomers, (R)-ketamine, esketamine, ketamine metabolites, norketamine, hydroxynorketamine, serotonin release, dopamine release, noradrenaline release, prefrontal cortex, AMPA receptors, NBQX, antidepressant mechanism, lipopolysaccharide-induced depression, monoaminergic neurotransmission
- MeSH terms
- Animals, Disease Models, Animal, Dopamine, Dose-Response Relationship, Drug, Ketamine, Lipopolysaccharides, Male, Microinjections, Norepinephrine, Quinoxalines, Serotonin, Stereoisomerism, Prefrontal Cortex, Microdialysis, Receptors, AMPA, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.